MRA Advisory Group Makes New Investment in Halozyme Therapeutics, Inc. $HALO

MRA Advisory Group bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,713 shares of the biopharmaceutical company’s stock, valued at approximately $741,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares during the last quarter. Bank of America Corp DE acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $214,504,000. William Blair Investment Management LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $196,540,000. Royal London Asset Management Ltd. grew its position in Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after purchasing an additional 200,262 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $105,570,000. 97.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HALO shares. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $2.08 during mid-day trading on Wednesday, hitting $111.80. 1,155,466 shares of the stock traded hands, compared to its average volume of 1,926,080. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $116.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company’s 50-day simple moving average is $104.56 and its 200-day simple moving average is $82.20. The firm has a market cap of $12.69 billion, a price-to-earnings ratio of 33.36, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares in the company, valued at $6,339,313.86. The trade was a 24.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 85,852 shares of company stock worth $9,158,446. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.